• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Magn Reson Imaging . Low Prevalence of Late Myocardial Injury on Cardiac MRI Following COVID-19 Infection

tetano

Editor, Senior Moderator
J Magn Reson Imaging


. 2023 Mar 5.
doi: 10.1002/jmri.28668. Online ahead of print.
Low Prevalence of Late Myocardial Injury on Cardiac MRI Following COVID-19 Infection


Ady Orbach[SUP] 1 [/SUP], Nilesh R Ghugre[SUP] 1 2 3 [/SUP], Labonny Biswas[SUP] 1 [/SUP], Kim A Connelly[SUP] 4 [/SUP], Adrienne Chan[SUP] 5 [/SUP], Bradley H Strauss[SUP] 1 [/SUP], Graham A Wright[SUP] 1 2 3 [/SUP], Idan Roifman[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The prevalence of abnormal cardiac magnetic resonance imaging (MRI) findings indicative of myocardial injury in patients who recovered from coronavirus disease 2019 (COVID-19) is currently unclear, with a high variability in the reported prevalence.
Purpose: To assess the prevalence of myocardial injury after a COVID-19 infection.
Study type: Prospective, bicentric study.
Subjects: Seventy consecutive patients who recovered from COVID-19 and were previously hospitalized. Mean age was 57 years and 39% of the patients were female. Ten healthy controls and a comparator group of 75 nonischemic cardiomyopathy (NICM) patients were employed.
Field strength/sequence: 1.5-T, steady-state free precession (SSFP) gradient-echo sequence, modified Look-Locker inversion recovery sequence with balanced SSFP readout, T2-prepared spiral readout sequence and a T1-weighted inversion recovery fast gradient-echo sequence was acquired ~4-5 months after recovery from COVID-19.
Assessment: The SSFP sequence was utilized for the calculation of left and right ventricular volumes and ejection fractions (LVEF and RVEF) following manual endocardial contouring. T1 and T2 mapping was performed by pixel-wise exponential fitting, and T1 and T2 values were computed by manual contouring of the left ventricular endocardial and epicardial walls. Late gadolinium enhancement (LGE) images were graded qualitatively as LGE present or absent.
Statistical tests: T-tests and the χ[SUP]2[/SUP] or Fisher's exact tests were used to compare continuous and categorical variables respectively between the COVID-19 and NICM groups. Inter-rater agreement was evaluated by the intraclass correlation coefficient for continuous variables and Cohen's kappa test for LGE.
Results: Reduced RVEF occurred in 10%, LGE and elevated native T1 in 9%, reduced LVEF in 4%, and elevated T2 in 3% of COVID-19 patients, respectively. Patients with NICM had lower mean LVEF (41.6% ± 6% vs. 60% ± 7%), RVEF (46% ± 5% vs. 61% ± 9%), and a significantly higher prevalence of LGE (27% vs. 9%) when compared to those post-COVID-19.
Data conclusion: Abnormal cardiac MRI findings may show a low prevalence in patients who recovered from COVID-19 and were previously hospitalized.
Level of evidence: 2 TECHNICAL EFFICACY: Stage 2.

Keywords: COVID-19; cardiac; myocardial injury; myocarditis.
 
Back
Top Bottom